KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Acquisitions: 2010-2018

Historic Acquisitions for Emergent BioSolutions (EBS) over the last 6 years, with Dec 2018 value amounting to $827.7 million.

  • Emergent BioSolutions' Acquisitions fell 46.37% to $650,000 in Q4 2015 from the same period last year, while for Dec 2015 it was $181.8 million, marking a year-over-year decrease of 11.43%. This contributed to the annual value of $827.7 million for FY2018, which is 604.43% up from last year.
  • Emergent BioSolutions' Acquisitions amounted to $827.7 million in FY2018, which was up 604.43% from $117.5 million recorded in FY2017.
  • In the past 5 years, Emergent BioSolutions' Acquisitions ranged from a high of $827.7 million in FY2018 and a low of $650,000 during FY2015.
  • Its 2-year average for Acquisitions is $472.6 million, with a median of $472.6 million in 2017.
  • In the last 5 years, Emergent BioSolutions' Acquisitions plummeted by 99.64% in 2015 and then surged by 604.43% in 2018.
  • Emergent BioSolutions' Acquisitions (Yearly) stood at $179.4 million in 2014, then crashed by 99.64% to $650,000 in 2015, then reached $117.5 million in 2017, then surged by 604.43% to $827.7 million in 2018.